Emerging MOAs in Multiple Myeloma: Updates From the 17th IMW | Special Issues

Dr. Richardson on Preliminary Data With Belantamab Mafodotin in Multiple Myeloma

December 12, 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the preliminary data that has been reported with belantamab mafodotin (GSK2857916) in multiple myeloma.

Novel Therapies Surge Forward in Relapsed/Refractory Multiple Myeloma

November 26, 2019

Thomas G. Martin, MD, provides insight into novel therapies under evaluation in relapsed/refractory multiple myeloma and the steps that need to be taken prior to and upon the use of these approaches in clinical practice.

Dr. Usmani on DREAMM Trials in Multiple Myeloma

October 09, 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the DREAMM-1 and DREAMM-2 trials in multiple myeloma.